SALUBRISBIO

Serial Number 87425888
Registration 5748146
700

Registration Progress

Application Filed
Apr 26, 2017
Under Examination
Nov 14, 2017
Approved for Publication
Sep 19, 2017
Published for Opposition
Feb 26, 2019
Registered
May 14, 2019

Trademark Image

SALUBRISBIO

Basic Information

Serial Number
87425888
Registration Number
5748146
Filing Date
April 26, 2017
Registration Date
May 14, 2019
Published for Opposition
February 26, 2019
Drawing Code
5

Status Summary

Current Status
Active
Status Code
700
Status Date
May 14, 2019
Registration
Registered
Classes
005

Rights Holder

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

99
Address
37F, Main Tower, Lvjing Plaza,
Che Gong Miao, No. 6009 Shennan Road,
Futian Dist., Shenzhen 518040
CN

Ownership History

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Original Applicant
99
Futian Dist., Shenzhen CN

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Owner at Publication
99
Futian Dist., Shenzhen CN

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Original Registrant
99
Futian Dist., Shenzhen CN

Legal Representation

Attorney
Timothy T. Wang

Application History

37 events
Date Code Type Description Documents
May 14, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
May 14, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Feb 26, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 26, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 6, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 25, 2019 MREI O NOTICE OF REINSTATEMENT MAILED Loading...
Jan 23, 2019 ADBS I 1(B) BASIS DELETED; NEW BASIS REQUESTED Loading...
Jan 22, 2019 RGIA O REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED Loading...
Jan 22, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Dec 17, 2018 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Dec 17, 2018 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Nov 14, 2018 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Oct 9, 2018 PCBG O PETITION TO DIRECTOR - CHANGE BASIS - GRANTED Loading...
Oct 5, 2018 APET A ASSIGNED TO PETITION STAFF Loading...
Sep 24, 2018 TPAD I TEAS PETITION TO AMEND BASIS RECEIVED Loading...
Sep 22, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 21, 2018 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 6, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jul 18, 2018 NREV E NOTICE OF REVIVAL - E-MAILED Loading...
Jul 17, 2018 TPEX I SOU EXTENSION RECEIVED WITH TEAS PETITION Loading...
Jul 17, 2018 PETG O PETITION TO REVIVE-GRANTED Loading...
Jul 17, 2018 PROA I TEAS PETITION TO REVIVE RECEIVED Loading...
Jun 18, 2018 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Jun 18, 2018 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
May 14, 2018 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 14, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 19, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 19, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 30, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 27, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 27, 2017 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 27, 2017 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 27, 2017 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jul 27, 2017 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 24, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
May 3, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 29, 2017 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Medicines for human purpose, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biological preparations for medical purposes, namely, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biochemical medicines, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Drugs for medical purposes in the nature of medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Injections, namely, vaccines and injectable medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of components of finished pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Dietetic substances adapted for medical use, namely, dietetic beverages and food for medical purposes, the foregoing dietetic food and beverages containing vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, restoratives, plant fibre, nutrition powder, nutrient capsule, nutrient tablets, and containing mineral food-supplements, the foregoing dietetic foods and beverages are used for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases

Additional Information

Design Mark
The mark consists of stylized word of "SalubrisBio".
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005